Acusphere, Inc.
Acusphere, Inc. Reports Q3 2008 Financial Results and Business Highlights
Published in Food and Drug Law Weekly, November 28th, 2008
Recent Developments
Following the close of the third quarter, Acusphere announced a definitive agreement with Cephalon, Inc. to provide Acusphere with $20.0 million in upfront financing through the issuance of a $15.0 million senior secured convertible note and a $5.0 million upfront fee for an exclusive worldwide license to AI-525, a preclinical-stage injectable formulation of celecoxib using Acusphere's proprietary Hydrophobic Drug Delivery System (HDDS(TM)) technology. The...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
More Articles from Food and Drug Law Weekly
- Fibrosis
Co-Sponsorship of Pulmonary Fibrosis Research Enhancement Act Increases to 27 Members - Life Sciences
AAMC Urges Congress to Stimulate the Economy Through Increased Support for NIH and Medical Education - Mental Health
Studies from Institute of Mental Health Research, Health Research Division have provided new information about mental health - Acorda Therapeutics, Inc.
Acorda Therapeutics Names Thomas C. Wessel, M.D., Ph.D., as Chief Medical Officer - American Academy of Dermatology
Is There Really Such a Thing as Hope in a Jar? - Anthrax Vaccines
Studies from W.W. Kwok and co-researchers update current data on anthrax vaccines - More from this issue of Food and Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
